

COURSE FACULTY, IAS–USA STAFF, SCIENTIFIC LEADERSHIP BOARD, AND GOVERNANCE BOARD

FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as “commercial interests”) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months. View the [Faculty Financial Disclosure Policy](#).

LOS ANGELES, CALIFORNIA – SEPTEMBER 8, 2022

Course Presenters	
Roger J. Bedimo, MD, MS Professor of Medicine University of Texas Southwestern Medical Center VA North Texas Health Care System Dallas, Texas	Dr Bedimo has received research funding from ViiV Healthcare and Merck & Co. Inc, and serves on the Scientific Advisory Board for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, and Theratechnologies. (Updated 9/6/22)
Judith S. Currier, MD, MSc Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles, California	Dr Currier has served as a consultant to Merck & Co., Inc. (Updated 08/17/22)
Nadine Kaslow, PhD, ABPP Professor, Psychiatry and Behavioral Sciences Emory University Atlanta, Georgia	Dr Kaslow has no relevant financial relationships with ineligible companies to disclose. (Update 04/17/22)
Raphael J. Landovitz, MD, MSc Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles, California	Dr Landovitz has served on scientific advisory boards for Gilead Sciences, Inc., and Merck & Co., Inc., and served as a consultant to Cepheid. (Updated 08/18/22)
Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama	Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 8/30/22)
Melanie Thompson, MD Thacker & Thompson, MD Atlanta, Georgia	Dr Thompson's institution received research grants from Gilead Sciences, Inc, Merck Sharp Dohme, and ViiV Healthcare. She currently chairs a data safety monitoring board for Excision Biotherapeutics. (Updated 09/01/22)
IAS–USA CME Planners and Reviewers	
Constance A. Benson, MD Professor of Medicine and Global Public Health Divisions of Infectious Diseases and Global Public Health ID Training Program Director Director, Antiviral Research Center PI/Director, HIV/AIDS Clinical Trials Unit University of California San Diego San Diego, California	Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. (Updated 09/02/22)
Nadine Kaslow, PhD, ABPP	Dr Kaslow has no relevant financial relationships with ineligible companies to disclose. (Update 04/17/22)
Raphael J. Landovitz, MD, MSc	Dr Landovitz has served on scientific advisory boards for Gilead Sciences, Inc., and Merck & Co., Inc., and served as a consultant to Cepheid. (Updated 08/18/22)
Donna M. Jacobsen Executive Director/President IAS–USA	Ms Jacobsen has no relevant financial affiliations with ineligible companies to disclose. (Updated 09/07/22)

IAS–USA Boards

The nonstaff members of the [IAS–USA Scientific Advisory Board](#) and [Governance Board](#) are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.